News

Link to ASCO position statement on phase I clinical trials .::. Link

During 2014, START Madrid - CIOCC has treated 181 new patients!! This makes a total of 681 patients treated since the Unit opened in October of 2008.

November 2014: START Madrid - CIOCC receives the Clinical Research Site Award from INC Research.

INC Research team members had the following comments in nominating START Madrid - CIOCC for this recognition:

  • This site is the best site I ever had in more than 10 years as a CRA. The investigators and staff are highly qualified, efficient and clearly involved in the study. The PI is always collaborative and reachable.
  • The site exceeded the contracted number of evaluable patients on schedule. 
  • The site has a demonstrated regulatory compliance regarding informed consent administration, accurate drug accountability, prompt reporting of SAEs, regulatory binder maintenance and timely submission of essential documents.  They have a broad protocol knowledge that has been shown throughout the study by all the site´s staff.  Low number of protocol deviations.  The required time lines are always met. The source documentation is complete, accurate and legible.  The CRF is always completed on time.  Queries are resolved almost as soon as they are created. 
  •       
  • Despite the high number of staff taking part in the study, they are always coordinated and demonstrate strong teamwork. All of the team is highly engaged.
  •      
  • Timely and clear communication, a proactive approach and a detailed understanding of the protocol has ensured that patients have received study treatment per the protocol.

May 2014: START Madrid – FJD receives the Credential for Excellence in Good Clinical Practice by Spanish Government.

October 2011 : START Madrid – CIOCC is the first Phase I Unit that obtains the Spanish government's Credential for Excellence in Good Clinical Practice .

 

 

START A Global Company

"Our sole mission is to accelerate the development of new therapies for the treatment and eventual cure of cancer by taking the skills and expertise that has been created here and expanding it to the rest of the world.”  

--Dr. Anthony Tolcher